Antibody Drug Conjugates Contract Manufacturing Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 8.44 Billion |
| Market Size (2029) | USD 30.84 Billion |
| CAGR (2024 - 2029) | 29.60 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Antibody Drug Conjugates Contract Manufacturing Market Analysis
The Antibody Drug Conjugates Contract Manufacturing Market size is estimated at USD 8.44 billion in 2024, and is expected to reach USD 30.84 billion by 2029, growing at a CAGR of 29.60% during the forecast period (2024-2029).
The COVID-19 pandemic had an enormous influence on the healthcare domain, significantly disrupting the whole supply chain, from raw materials to production and delivery. An optimistic and conscious approach to the development of monoclonal antibodies and other ADCs was driven into the spotlight as potential treatments for COVID-19. The pandemic created a sturdy and quick reaction from scientists working for governments and industries to produce medicines and vaccines. As a consequence of the demand for effective medicines for the treatment of COVID-19, the global production of antibody-drug conjugates, vaccines, and other pharmaceuticals expanded. Besides, ADCs are more complex to manufacture, which is likely to create more demand for contract manufacturing organizations.
Antibody-drug conjugates are complex, potent biologics that offer significant potential to address critical diseases, including cancer. The clinical potential of these therapeutics is attributed to their ability to effectively target disease-associated cells while minimizing off-target toxicity. Notably, with time and advancements in research, scientists have further improved the design and development process for these therapies. This has resulted in the approval of four new ADCs in 2020. To date, the USFDA has approved 12 antibody-drug conjugates, and 100 are in development.
Also, as per the ADC Review in 2021, around 70% of antibody-drug conjugate projects are outsourced to contract development and manufacturing organizations (CDMOs), and with the continued expansion of the pipelines, this trend is likely to endure further. As more commercial products reach the market, there is an acute need for contract development and manufacturing organizations that know the way to execute late-stage studies to support the filing strategy. CMOs, with plans to support commercial-scale antibody-drug conjugate manufacturing by setting up processes to handle challenging supply chains by investing in facilities and processes to ensure security, quality, and efficiency, are expected to contribute to the growth of the market over the forecast period. Hence, given the anticipated growth in the demand for antibody-drug conjugates, the contract manufacturing market for antibody-drug conjugates is also expected to witness significant growth in the coming years.
Antibody Drug Conjugates Contract Manufacturing Market Trends
The Cleavable Linker Segment is Expected to Hold a Major Market Share in the Antibody-Drug Conjugates Contract Manufacturing Market
The growth of the segment is largely attributed to the extensive use of cleavable linker technology in antibody-drug conjugates and a greater number of cleavable linker-based authorized products. ADCs are now recognized as a main class of therapeutics for the clinical treatment of cancer. The properties of the linker between the payload and the antibody are proven to be vital to the success of an antibody-drug conjugate. Even though the antibody-drug conjugate linkers can be non-cleavable, the majority of antibody-drug conjugates in clinical development have specific release mechanisms to allow controlled linker cleavage at the target site and are termed "cleavable". The cleavable linkers are the major class of antibody-drug conjugate linkers. The main feature of cleavable linkers is that they are cleaved by environmental differences and particular lysosomal enzymes in response to extracellular and intracellular environments.
As per an article published by NCBI in April 2020, about two-thirds of antibody-drug conjugates used cleavable linkers in clinical trials. As per the article, Antibody-drug conjugates: Recent advances in linker chemistry, more than 80% of the clinically approved antibody-drug conjugates employ cleavable linkers.
The above-mentioned factors are expected to drive the demand for the growth of the segment studied during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period.
Favorable government support in the United States related to the approval of antibody-drug conjugates (ADCs) is driving the growth of the market. As of May 2021, the USFDA had approved ten antibody-drug conjugates for breast cancer, urothelial cancer, myeloma, acute leukemia, and lymphoma.
Besides, the increase in the prevalence of cancer in the United States and the country's greater spending capacity for novel therapeutics are creating more demand for antibody-drug conjugates, which, in turn, is leading to increased investment in the development and manufacturing of antibody-drug conjugates. According to the American Cancer Society, the estimated new numbers of cancer cases were 1.9 million in 2021 in the United States, and the same source projected that the new number of cancer cases would be 1.9 million in 2022.
Additionally, according to the National Cancer Institute, breast cancer is the most common cancer, with 290,560 new cases projected in the United States in 2022. Prostate cancer and lung cancer are the next most frequent cancers in the country. Increasing awareness about current therapies, the high prevalence of cancer, significant R&D expenditure, and the presence of major players are supporting the market growth in the region. For instance, MilliporeSigma has deep expertise in relevant capabilities, including monoclonal antibodies, linkers, highly potent compounds, and conjugation technologies, and it continues to build on its end-to-end capabilities. The company is also excited to increase the number of commercial products produced at its facility in the United States, the first CDMO site approved for commercial ADC manufacturing in the United States.
Additionally, the key market players' investments and strategies are expected to drive the growth of the market. For instance, in September 2020, Merck announced a USD 59 million expansion of its ADC and HPAPI manufacturing capabilities at its facility near Wisconsin, United States. This investment is likely to allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer.
Thus the above-mentioned factors are expected to drive the growth of the market studied in this region during the forecast period.
Antibody Drug Conjugates Contract Manufacturing Industry Overview
The antibody-drug conjugates contract manufacturing market is fragmented in nature, with several regional as well as international players. Some companies currently dominating the market are Lonza Group, Piramal Pharma Solutions, Abbvie Inc., Novasep, Merck KGaA, Cambrex Corporation, Recipharm, Thermo Fisher Scientific Inc., Cerbios-Pharma SA, and Sterling Pharma Solutions.
To gain a competitive edge, companies are putting in noteworthy efforts and capital investments toward expanding their capabilities, thereby enhancing their respective service portfolios. Some firms have also established new facilities dedicated to the manufacturing of highly potent compounds. The field has also observed the establishment of various partnerships between drug developers and ADC manufacturers.
Antibody Drug Conjugates Contract Manufacturing Market Leaders
-
Lonza Group
-
Abbvie, Inc.
-
Merck KGaA
-
Cambrex Corporation
-
Recipharm
*Disclaimer: Major Players sorted in no particular order
Antibody Drug Conjugates Contract Manufacturing Market News
- July 2022: WuXi XDC and AbTis signed a memorandum of understanding to form a partnership to develop and manufacture antibody-drug conjugates.
- In February 2022: Piramal Pharma invested over USD 53.42 million for the expansion of its antibody-drug conjugate capabilities at the Grangemouth facility in Scotland and is investing in new active pharmaceutical ingredient infrastructure at its Morpeth facility in England.
Antibody Drug Conjugates Contract Manufacturing Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing burden of Cancer Cases
4.2.2 Increasing R&D Activities Pertaining to Antibody Drug Conjugates
4.2.3 Growing Demand for Biologic Therapy
4.3 Market Restraints
4.3.1 R&D and Production Challenges
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Linker
5.1.1 Cleavable Linker
5.1.2 Non-Cleavable Linker
5.2 By Application
5.2.1 Myeloma
5.2.2 Lymphoma
5.2.3 Breast cancer
5.2.4 Other Applications
5.3 By Phase
5.3.1 Clinical
5.3.2 Commercial
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Lonza Group
6.1.2 Piramal Pharma Solutions
6.1.3 Abbvie Inc.
6.1.4 Novasep
6.1.5 Merck KGaA
6.1.6 Cambrex Corporation
6.1.7 Recipharm
6.1.8 Thermo Fisher Scientific Inc.
6.1.9 Cerbios-Pharma SA
6.1.10 Sterling Pharma Solutions
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Antibody Drug Conjugates Contract Manufacturing Industry Segmentation
Antibody-drug conjugates (ADC) are a class of biopharmaceuticals designed for cancer treatment that comprise an antibody that specifically targets a tumor antigen and a cytotoxic compound associated with a chemical linker. They are intended to allow the precise targeting of the cytotoxic compound to kill tumor cells while having a limited effect on healthy tissue. As ADCs are a novel class of biopharmaceuticals, the production of such complex products requires both chemical and biological know-how. Contract manufacturing organization provides technical knowledge in conjugation and linker creation, as well as solid platforms.
The antibody-drug conjugates contract manufacturing market is segmented by linker (cleavable linker and non-cleavable linker), application (myeloma, lymphoma, breast cancer, and other applications), phase (clinical and commercial), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers values in USD million for the abovementioned segments.
| By Linker | |
| Cleavable Linker | |
| Non-Cleavable Linker |
| By Application | |
| Myeloma | |
| Lymphoma | |
| Breast cancer | |
| Other Applications |
| By Phase | |
| Clinical | |
| Commercial |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Antibody Drug Conjugates Contract Manufacturing Market Research FAQs
How big is the Antibody Drug Conjugates Contract Manufacturing Market?
The Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 8.44 billion in 2024 and grow at a CAGR of 29.60% to reach USD 30.84 billion by 2029.
What is the current Antibody Drug Conjugates Contract Manufacturing Market size?
In 2024, the Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 8.44 billion.
Who are the key players in Antibody Drug Conjugates Contract Manufacturing Market?
Lonza Group, Abbvie, Inc., Merck KGaA, Cambrex Corporation and Recipharm are the major companies operating in the Antibody Drug Conjugates Contract Manufacturing Market.
Which is the fastest growing region in Antibody Drug Conjugates Contract Manufacturing Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Antibody Drug Conjugates Contract Manufacturing Market?
In 2024, the North America accounts for the largest market share in Antibody Drug Conjugates Contract Manufacturing Market.
What years does this Antibody Drug Conjugates Contract Manufacturing Market cover, and what was the market size in 2023?
In 2023, the Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 5.94 billion. The report covers the Antibody Drug Conjugates Contract Manufacturing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Antibody Drug Conjugates Contract Manufacturing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Antibody Drug Conjugates Contract Manufacturing Industry Report
Statistics for the 2024 Antibody Drug Conjugates Contract Manufacturing market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Antibody Drug Conjugates Contract Manufacturing analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
